pharma · Idiopathic Pulmonary Fibrosis · Prevention of breast cancer in women with a BRCA1 germline mutation
Shanghai Zerun Biotechnology
Shanghai Reinovax Biologics Co.,LTD
Shanghai Zerun Biotechnology is a pharma organization headquartered in Shanghai, CN. Primary therapeutic focus areas include Idiopathic Pulmonary Fibrosis, Prevention of breast cancer in women with a BRCA1 germline mutat
Company details
- Status
- Public
- HQ
- 936号 Zhangheng Rd, Shanghai 201203, CN
- Employees
- 21
- Programs
- 11
- Drugs
- 33
- Patents
- 11
BRCA-P/ABCSG 50
Phase 3 · small molecule · Prevention of breast cancer in women with a BRCA1 germline mutation
BRCA-P/ABCSG 50 for Prevention of breast cancer in women with a BRCA1 germline mutation is a Phase 3 program (small_molecule) at Shanghai Reinovax Biologics Co.,LTD with 1 ClinicalTrials.gov record(s).
Internal code BRCA-P/ABCSG 50
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Reinovax Biologics Co.,LTD
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Prevention of breast cancer in women with a BRCA1 germline mutation
- Status
- active
- Trials
- 1